INVESTORS

09/05/2022: eureKING_Prospectus

09/05/2022: eureKING Launch Press Release_English

09/05/2022: eureKING Launch Press Release_Annex_French

10/05/2022: eureKING Results Press Release_English

13/09/2022: SPAC eureKING Obtains the TIBI label and Strengthens Its Status as a Prime Investor for the Creation of a Major Biomanufacturing Player in Europe

30/12/2022: Interim Financial Report For The Six-Month Period Ended September 30, 2022

30/12/2022: Press Release on Interim Financial Report HY 2022 EN

French Version

28/04/2023:Financial Report for the Period Ending December 31^st, 2022

28/04/2023: Press Release on Financial Report FY 2022 EN

                         French Version

16/05/2023: Press Release on Intention to Combine with Skyepharma to Build a New European Bio-CDMO leader

                         French Version

30/05/2023: Press Release on eureKING Skyepharma Put Option Announcement

                       French Version

30/06/2023: eureKING Combined General Meeting of June 30, 2023 – Voting results 

                       French Version

30/06/2023: eureKING Special General Meeting of market shareholders of June 30, 2023 – Voting results 

                       French Version

07/07/2023: Press Release on eureKING Skyepharma acquisition project: favorable opinion issued by Skyepharma’s workers’council on the proposed acquisition by eureKING 

                       French Version

07/07/2023:

All documents relating to the 2023 Annual General Meeting can be found here.

Please see all documents relating to the meetings (the Extraordinary General Meeting, Founders’ Shares A1, A2 and A3 and Market Shares Special Meetings and the Founders’ Warrants and Market Warrants Special Meetings) on August 11, 2023 here.

24/07/2023: Press Release on eureKING Availability of the preparatory documents relating to the meetings convened on August 11, 2023

                       French Version

08/08/2023: Press Release – eureKING and Skyepharma revise the terms of their business combination

                        French Version

09/08/2023: Press Release – eureKING announces the signing of an agreement to purchase full ownership interest in SCTbio, taking a step closer in building a new European bio-CDMO leader

                       French Version

11/08/2023: eureKING Presentation

11/08/2023: Press Release – eureKING AGE and Special meetings

                        French Version

21/08/2023: Press Release – Notice of Redemption

                         French Version

01/09/2023: Press Release – Proposed IBC with Skyepharma and Proposed Acquisition of SCTbio

                         French Version

Related documents:

04/09/2023: SCTbio’s statutory unaudited Czech GAAP financial statements for the fiscal year ended December 31, 2022

04/09/2023: Etats financiers de Skyepharma French GAAP pour l’exercice clos le 31 décembre 2022 et Rapport d’audit

04/09/2023: Etats financiers de Skyepharma French GAAP pour l’exercice clos le 31 décembre 2021 et rapport d’audit

04/09/2023: Etats financiers de Skyepharma French GAAP pour l’exercice clos le 31 décembre 2020 et rapport d’audit

04/09/2023: Comptes consolidés audités en normes IFRS d’Oleron Pharma pour les exercices clos les 31 décembre 2021 et 2022 et Rapport d’audit

17/09/2023: eureKING – Publication site internet sur conventions réglementées 2023

21/09/2023: eureKING Press release – Interim financial report 2023

                         French Version

21/09/2023: Interim Financial Report for the six-month period ended June 30, 2023

22/09/2023: Press Release – Results of the redemption requests of eureKING’s Market Shares

                       French Version